Implementation of different algorithms for analyzing
        randomly truncated data, one-sided and two-sided (i.e. doubly)
        truncated data. It serves to compute empirical cumulative 
        distributions and also kernel density and hazard functions 
        using different bandwidth selectors.
      Several real data sets are included.

Nonparametric estimator of the cumulative incidences of competing risks under double truncation. The estimator generalizes the Efron-Petrosian NPMLE (Non-Parametric Maximun Likelihood Estimator) to the competing risks setting. Efron, B. and Petrosian, V. (1999) <doi:10.2307/2669997>.

Non-iterative estimator for the cumulative distribution of a doubly truncated variable. de Uña-Álvarez J. (2018) <doi:10.1007/978-3-319-73848-2_37>.

Provides functions for planning clinical trials subject to a delayed
    treatment effect using assurance-based methods. Includes two 'shiny'
    applications for interactive exploration, simulation, and visualisation of
    trial designs and outcomes. The methodology is described in:
    Salsbury JA, Oakley JE, Julious SA, Hampson LV (2024)
    "Assurance methods for designing a clinical trial with a delayed treatment
    effect" <doi:10.1002/sim.10136>,
    Salsbury JA, Oakley JE, Julious SA, Hampson LV (2024)
    "Adaptive clinical trial design with delayed treatment effects using
    elicited prior distributions" <doi:10.48550/arXiv.2509.07602>.

Implements a Bayesian Optimal Phase II design (DTE-BOP2) for trials with delayed treatment effects, particularly relevant to immunotherapy studies where treatment benefits may emerge after a delay. The method builds upon the BOP2 framework and incorporates uncertainty in the delay timepoint through a truncated gamma prior, informed by expert knowledge or default settings. Supports two-arm trial designs with functionality for sample size determination, interim and final analyses, and comprehensive simulation under various delay and design scenarios. Ensures rigorous type I and II error control while improving trial efficiency and power when the delay effect is present. A manuscript describing the methodology is under development and will be formally referenced upon publication.